# Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT00143065** · PHASE2 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 8 (actual)

## Conditions studied

- Lymphoma, Small Lymphocytic
- Lymphocytic Leukemia, Chronic

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Rituximab
- **DRUG:** Alemtuzumab

## Key facts

- **NCT ID:** NCT00143065
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2007-02
- **Final completion:** 2009-07
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2017-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00143065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00143065, "Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00143065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*